Safety and Performance Study of the Edwards CENTERA Self-Expanding Transcatheter Heart Valve
This trial is active, not recruiting.
|Condition||aortic valve disease|
|Treatment||edwards centera self-expanding transcatheter heart valve|
|Collaborator||Medstar Health Research Institute|
|Start date||February 2013|
|End date||October 2013|
|Trial size||34 participants|
|Trial identifier||NCT01808274, 2012-03|
The purpose of this study is to assess the safety and device success of the Edwards CENTERA Transcatheter Heart Valve (THV) System in patients with symptomatic, severe aortic stenosis who are indicated for aortic valve replacement.
|United States||No locations recruiting|
|Other countries||No locations recruiting|
|Bonn, Germany||Herzzentrum Universitaet Bonn||no longer recruiting|
|Hamburg, Germany||Asklepios Klinik St Georg Hamburg||no longer recruiting|
|Leipzig, Germany||Heart Center Leipzig||no longer recruiting|
|Bern, Switzerland||Inselspital Bern||no longer recruiting|
|Intervention model||single group assignment|
All-cause mortality rate
time frame: 30 days post-index procedure
time frame: 30 days
time frame: 1 year
All participants of any age.
Inclusion Criteria: 1. High surgical risk: STS Score ≥ 8,EuroSCORE ≥ 15. 2. NYHA ≥ II. 3. Heart team (including examining cardiac surgeon) agrees on eligibility including assessment that TAVR is appropriate. 4. Study patient is an adult of legal consent age. 5. Study patient has provided written informed consent to comply with all of the study procedures and follow-up visits. Exclusion Criteria: 1. Acute myocardial infarction ≤ 30 days before the intended treatment. 2. Untreated clinically significant coronary artery disease requiring revascularization. 3. Aortic valve is a congenital unicuspid or congenital bicuspid valve. 4. Mixed aortic valve disease (with predominant aortic regurgitation).
|Official title||Safety and Performance Study of the Edwards CENTERA Self-Expanding Transcatheter Heart Valve|
|Principal investigator||Prof. Windecker, MD|
|Description||This is a non-randomized, prospective, multi-center safety and device success study. 34 patients have been enrolled at 4 participating investigational centers in Europe. Patient participation will last for a minimum of 5 years. Patients will be assessed at the following intervals: baseline, discharge, 30 days, 6 months, 1 year and annually thereafter through 5 years|
Call for more information